Innovation Pharmaceuticals Inc (IPIX)

[GreenBioAnalyst]

Severe vs critically ill are two different criteria of cv19 (sequela) patients. They're not the same. Understand this.
He definitely needs a CMO advisor. At least severe since that's where ARDS, pneumonia, and SEPSIS that Bril can address.
So he's just gonna just sit and milk the phase II results using grant funding?
That's bad advice. You cannot maximize shareholders' wealth without taking risks for both severe and critically ill patients. The primary endpoints are now secondary. I'm sure our results with Bril in mortality rate will be better than REMDESIVIR (THRASH).

I can guarantee you that Bril is as good or even better than Leronlimmab. BUT NOW IS NOT THE TIME TO SECOND GUESS BRIL'S 3-IN-1 ACTION. SEIZE THE DAY! LET THE JUGGERNAUT DOES ITS THING IN CV19 PATIENTS!